Document is current
Any future updates will be listed below
-
Authors
Bogdanov, Mario https://orcid.org/0000-0003-2386-3557
Scott, Jason N. Jr
Esfand, Shiba M.
Boyle, Brian W.
Lees, Ty
Li, Mohan
Woronko, Sarah E.
Linton, Samantha R.
Miller, Courtney
Li, Shuang
Bolton, Paula
Meisner, Robert C.
Pizzagalli, Diego A.
-
Funding
Funding for this research was provided by:
Millennium Pharmaceuticals
- License Information
-
More Information
Article History
Accepted: 27 June 2025
First Online: 11 August 2025
Declarations
:
: Over the past 3 years, Dr. Pizzagalli has received consulting fees from Boehringer Ingelheim, Compass Pathways, Engrail Therapeutics, Karla Therapeutics, Neumora Therapeutics (formerly BlackThorn Therapeutics), Neurocrine Biosciences, Neuroscience Software, Sage Therapeutics, Sama Therapeutics, and Takeda; he has received honoraria from the American Psychological Association, Psychonomic Society and Springer (for editorial work) and Alkermes; he has received research funding from the Bird Foundation, Brain and Behavior Research Foundation, Dana Foundation, DARPA, Millennium Pharmaceuticals, NIMH, and Wellcome Leap; he has received stock options from Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, and Neuroscience Software. All views expressed are solely those of the authors. All other authors have no conflicts of interest or relevant disclosures.
: Study procedures were conducted in accordance with the Declaration of Helsinki and were approved by the MGB Healthcare Institutional Review Board.
: Informed consent was obtained from all individual participants included in the study.
: Not applicable
: Dr. Pizzagalli serves as Editor-in-Chief at CABN. His role had no influence in journal choice, nor was he involved in the editorial process or peer-review activity.
